The Humanion UK Online Daily

The Elleesium: England: UK: Year Ninth: Day 13: Friday: October 06: 2023: Cogito Ergo Sum: Descartes

Elleesium Group of Publications

|| Hope Is the Seed Sign and Science of Progress: Join and Support Us ||

As the Mother Earth Belongs to Every Single Human Being of the Humanion Regine Humanics Foundation Ltd and The Humanion Belong to All for We are a Human Enterprise: A Not for Profit Social Enterprise: Support Your Daily Quality Newspaper and Let Us Build an Institution That Will Flow with Time with the Rainbow Peoples of This Earth Far Into the Flowing Future: Support The Humanion: Support Regine Humanics Foundation Ltd

Humanicsxian Economics

|| The First Epidemiological Study Links Popular Weight-loss Drugs to Stomach Paralysis and Other Serious Gastro-intestinal Conditions ||

 

|| Friday: October 06: 2023 || ά. First epidemiological study links popular weight-loss drugs to stomach paralysis, other serious gastro-intestinal conditions. They’re being hailed as an effective way to lose weight but diabetes drugs like Ozempic may come with a heightened risk of severe gastro-intestinal problems.

That’s according to new research from the University of British Columbia showing that medications, known as GLP-1 agonists, which includes brands like Wegovy, Ozempic, Rybelsus and Saxenda, are associated with an increased risk of serious medical conditions, including stomach paralysis, pancreatitis and bowel obstruction. ::::ω::::

|| Readmore at thehumanion.com ||   reginehumanicsfoundation.com || 061023 ||

 

 

 

|| Malaria Kills Nearly Half a Million Children in the African Region Every Year: The World Health Organisation Recommends R21:Matrix-M Vaccine For Malaria Prevention ||

 

|| Monday: October 02: 2023 || ά. The World Health Organisation:WHO has recommended a new vaccine, R21:Matrix-M, for the prevention of malaria in children. The recommendation follows advice from the WHO: Strategic Advisory Group of Experts on Immunisation:SAGE and the Malaria Policy Advisory Group:MPAG and was endorsed by the WHO Director-General, following its regular bi-annual meeting, held on September 25-29.

The R21 and RTS.S vaccines act against P. falciparum, the deadliest malaria parasite and the most prevalent on the African continent. The updated WHO recommendation for malaria vaccines was informed by the results of the WHO-co-ordinated Malaria Vaccine Implementation Programme, through which nearly two million children in Ghana, Kenya and Malawi have been reached with the RTS.S:AS01 malaria vaccine since 2019. ::::ω::::

|| Readmore at thehumanion.com/Medicine.htm ||   reginehumanicsfoundation.com || 031023 ||

 

 

 

|| New Generation of Typhoid Vaccines Rolled Out Across Malawi ||

|| Sunday: September 17: 2023 || ά. Following successful vaccine trials in Malawi, more than 07 million children in the country have received Typhoid Conjugate Vaccine:TCV, in one of the largest immunisation campaigns ever conducted in the country. The vaccine is now being included as routine for all children going forward.

The first major advance in typhoid vaccines in a generation, TCV can improve immunological responses and memory and the trials have now proved that they offer increased efficacy over older vaccines, from around 55% to over 80%. The clinical trials of TCV, led by the Malawi-Liverpool-Wellcome Programme, were the first in Africa and showed that the vaccine was 84% effective to prevent episodes of typhoid and showed excellent safety and cost-effectiveness.

More than 28,000 children living in Malawi participated in the trial, which paved the way for national roll-outs in Malawi and other African countries. MLW is a partnership between the Kamuzu University of Health Sciences, the University of Liverpool and the Liverpool School of Tropical Medicine, with funding from the Wellcome Trust.

The trial followed 10 years of work, establishing the pattern and burden of rapidly-spreading Typhoid in Malawi. The need for the vaccine is, particularly, urgent because of recent increases in multi-drug antibiotic resistance across the continents of Africa and Asia. The University of Liverpool’s Professor Melita Gordon, the Head of the Salmonella Research Group at MLW and a UK NIHR Research Professor, said, “I am immensely proud of what has been achieved with our local participants, our teams of health workers, our local scientists, and our longstanding partners in the Malawi Ministry of Health and Kamuzu University of Health Sciences. Our typhoid research over more than a decade is now making a real impact on Malawi’s population health, preventing many illnesses, improving the lives of families and saving lives. We hope, to, soon, see more countries introduce TCV and help save more lives.”

Read more about the TCV programme in a blog from Dr Mike Chisema, an Expanded Program on Immunisation manager based in Malawi: https://www.coalitionagainsttyphoid.org/amidst-challenges-malawi-delivers-for-the-children

The clinical trial of TCV was funded by the Bill and Melinda Gates Foundation, and conducted in partnership with the Centre for Vaccine Development and Global Health:CVD at the University of Maryland School of Medicine. Financial support for the national roll-out in Malawi was made available through GAVI, the Vaccine Alliance for vaccines in countries with low and middle income. ::::ω::::

|| Readmore at thehumanion.com/Medicine.htm ||   reginehumanicsfoundation.com || 180923 ||